Resverlogix Corp.

Events/Webcasts

Webcasts & Presentations

Periocically Resverlogix will webcast from selected conferences/events. Active links will be posted here.

2016 Research & Development Update for apabetalone (RVX-208) in New York City.

Webcast can be accessed by clicking HERE

Full Presentation
Research & Development Update

Individual Presentations
Unmet Need in Diabetes and CVD & RVX MACE Analysis - Prof. Kausik Ray
Apabetalone: Current Research and Development - Ewelina Kulikowski, BSc, PhD
BETonMACE Clinical Update - Michael Sweeney, MD
Unmet Need in CKD & RVX MACE Analysis - Kamyar Kalantar-Zadeh, MD, PhD
Market Opportunity and Concluding Remarks - Donald J. McCaffrey, President & CEO

November 8, 2016, Resverlogix presented at BIO Europe in Cologne, Germany. Presentation PDF.

September 14th, 2016, Resverlogix presented a poster at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting. The eVideo presentation can be accessed here: https://youtu.be/dNtA5kPwpZg

September 14th, 2016, Resverlogix presented at the 9th Annual International Partnering Conference BioPharm America. Presentation PDF. 

September 13th, 2016, Resverlogix presented at the Rodman & Renshaw 18th Annual Global Investment Conference, NYC. Presentation PDF. Webcast link: http://wsw.com/webcast/rrshq26/RVX 

August 28th, 2016, Resverlogix hosted an Epigenetics Symposium at the ESC Congress 2016, titled: A novel approach for high CV risk patients with diabetes: The potential of epigenetics. Links to video presentations:

Prof. Kausik Ray, Imperial College, London, UK. http://www.pace-cme.org/video.aspx?id=4625

Dr. Jorge Plutzky, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA: http://www.pace-cme.org/video.aspx?id=4626

Prof. John Kastelein, Academic Medical Center, Amsterdam, Netherlands: http://www.pace-cme.org/video.aspx?id=4627

Current Events

Resverlogix will be attending several key industry conferences. Website will be udated as presentation opportunities become available. Please note: not all events offer a presentation opportunity and this list is subject to change.

December 15, 2016: Resverlogix Annual and Special Meeting of Shareholders

Mount Royal University, Roderick Mah Centre for Continuous Learning (Room EC1040)
4825 Mount Royal Gate SW
Calgary, Alberta, Canada
Meeting Commencing at 9:00AM (MST)
Webcast Commencing at approx. 9:30AM (MST)
Webcast Link: http://services.choruscall.ca/links/resverlogixagm20161215.html

January 9, 2017: 9th Annual Biotech Showcase Conference, San Francisco, CA

Resverlogix in the Media

March 29: CTV news filmed on location the RVX lab featuring the Sanofi Biogenius competition

January 20, 2016: Resverlogix featured in the Life Sciences Report

September 2015: At the 2015 Rodman & Renshaw healthcase conference, Don McCaffrey had a video interview with Stock News Now (SNN).

August 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey

June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.”

April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
 

April 27, 2015: BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China

April 28, 2015: BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. 

April 28, 2015: Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam.

April 28, 2015: BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. 

April 28, 2015: Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. 

April 28, 2015: GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M.

To arrange a media interview, please contact Sarah Zapotichny, Director of Investor Relations & Corporate Communications at sarah@resverlogix.com.